(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of 5.42% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.03%.
Organogenesis Holdings's revenue in 2024 is $433,140,000.On average, 1 Wall Street analysts forecast ORGO's revenue for 2024 to be $60,318,124,376, with the lowest ORGO revenue forecast at $60,318,124,376, and the highest ORGO revenue forecast at $60,318,124,376. On average, 1 Wall Street analysts forecast ORGO's revenue for 2025 to be $63,518,363,357, with the lowest ORGO revenue forecast at $63,518,363,357, and the highest ORGO revenue forecast at $63,518,363,357.
In 2026, ORGO is forecast to generate $66,748,294,053 in revenue, with the lowest revenue forecast at $66,748,294,053 and the highest revenue forecast at $66,748,294,053.